As this review discovered, repurposing of established noradrenergic drugs is most likely to offer effective treatment in Alzheimer’s disease for general cognition and apathy. Still, the report offers several factors that should be considered before designing future clinical trials.

The future certainly looks bright for patients diagnosed with multiple myeloma, as this opinion piece points out, thanks to combination therapies partnered with easily available, reliable minimal residual disease (MRD) assays. How close are we to a functional cure?

The International Consensus Classification (ICC) of myeloid neoplasms and acute leukemia was developed as a result of the recent advances in doctors’ understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials.

The analysis showed that autologous stem-cell transplant (ASCT) was underutilized in the US community setting, among other results. These data support ongoing prospective trials evaluating the role of ASCT in patients achieving complete response without detectable minimal residual disease.

Guideline-directed binary distinctions between HER2-positive and HER2-negative breast cancer have guided physicians’ treatment decisions for quite some time, but new research suggests that patients with HER2-2+, ISH-negative breast cancer present a clinical picture closer to that of patients with HER2-positive breast cancer, offering up a new nomenclature, HER2-low.

This six-chapter video series covers patient selection for neoadjuvant systemic treatment, adjuvant systemic treatment, neoadjuvant systemic treatment, post-neoadjuvant adjuvant treatment, survivorship and surveillance, and future directions.